PMID- 25608150
OWN - NLM
STAT- MEDLINE
DCOM- 20150730
LR  - 20220330
IS  - 1536-0229 (Electronic)
IS  - 0363-9762 (Linking)
VI  - 40
IP  - 3
DP  - 2015 Mar
TI  - Analysis of the roles of glucose transporter 1 and hexokinase 2 in the metabolism 
      of glucose by extrahepatic bile duct cancer cells.
PG  - e178-82
LID - 10.1097/RLU.0000000000000640 [doi]
AB  - PURPOSE OF THE REPORT: Extrahepatic bile duct (EHD) cancer varies in uptake of 
      FDG. The aim of the present study was to determine the role of glucose 
      transporter (GLUT) 1 and hexokinase (HK) 2 in the glucose metabolism of EHD 
      cancer cells using immunohistochemistry and 18F-FDG PET/CT. METHODS: Twenty-six 
      patients with EHD cancer who underwent baseline PET/CT and surgery were studied. 
      Biopsies were immunohistochemically analyzed using antibodies against GLUT1 and 
      HK2, and the expression was scored from 0 to 4 according to the percentage of 
      stained cells. SUV and tumor-to-liver ratio (T/L ratio) were obtained from 
      18F-FDG PET/CT data. SUV and T/L ratio and GLUT1 and HK2 expression were compared 
      with histological grades and tumor locations (proximal and distal EHD) to 
      correlate glucose metabolism with the expression of GLUT1 and HK2. RESULTS: SUV, 
      T/L ratio, and GLUT1 and HK2 expression did not differ as a function of 
      histological grade and tumor location. GLUT1 and HK2 were expressed in 20 (76.9%) 
      and 22 (84.6%) of 26 tumor biopsies, respectively. The GLUT1 score, SUV, and T/L 
      ratio increased, and the GLUT1 score, but not the HK2 score, correlated 
      significantly with SUV (rho = 0.648) and T/L ratio (rho = 0.703). There was no direct 
      correlation between the expression of GLUT1 and that of HK2 (rho = 0.2046, P = 
      0.3161). CONCLUSIONS: Although GLUT1 and HK2 regulate intracellular accumulation 
      of FDG in many cancers, only GLUT1 expression was correlated with FDG uptake by 
      EHD cancers.
FAU - Yoon, Sun Och
AU  - Yoon SO
AD  - From the Departments of *Pathology, daggerNuclear Medicine, double daggerSurgery, and  section signRadiology, 
      Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
FAU - Jeon, Tae Joo
AU  - Jeon TJ
FAU - Park, Joon Seong
AU  - Park JS
FAU - Ryu, Yong Hoon
AU  - Ryu YH
FAU - Lee, Jae-Hoon
AU  - Lee JH
FAU - Yoo, Jung Sik
AU  - Yoo JS
FAU - Kim, Jae Keun
AU  - Kim JK
FAU - Yoon, Dong Sup
AU  - Yoon DS
FAU - Oh, Eun Ji
AU  - Oh EJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Nucl Med
JT  - Clinical nuclear medicine
JID - 7611109
RN  - 0 (Glucose Transporter Type 1)
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (SLC2A1 protein, human)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - EC 2.7.1.1 (Hexokinase)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adenocarcinoma/*diagnostic imaging/metabolism/pathology
MH  - Aged
MH  - Aged, 80 and over
MH  - Bile Duct Neoplasms/*diagnostic imaging/metabolism/pathology
MH  - Bile Ducts, Extrahepatic/diagnostic imaging/metabolism/pathology
MH  - Female
MH  - Fluorodeoxyglucose F18
MH  - Glucose/*metabolism
MH  - Glucose Transporter Type 1/genetics/*metabolism
MH  - Hexokinase/genetics/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging
MH  - Positron-Emission Tomography
MH  - Radiopharmaceuticals
MH  - Tomography, X-Ray Computed
EDAT- 2015/01/22 06:00
MHDA- 2015/08/01 06:00
CRDT- 2015/01/22 06:00
PHST- 2015/01/22 06:00 [entrez]
PHST- 2015/01/22 06:00 [pubmed]
PHST- 2015/08/01 06:00 [medline]
AID - 10.1097/RLU.0000000000000640 [doi]
PST - ppublish
SO  - Clin Nucl Med. 2015 Mar;40(3):e178-82. doi: 10.1097/RLU.0000000000000640.